33696-00-3

Basic information

• Product Name: 4-BROMO-2-NITROANISOLE
• Synonyms: 4-BROMO-2-NITROANISOLE;1-Methoxy-2-nitro-4-bromobenzene;5-Bromo-2-methoxynitrobenzene;2-nitro-4-broMoanisole;3-Bromo-6-methoxynitrobenzene;4-Bromo-1-(methyloxy)-2-nitrobenzene;5-Bromo-2-methoxynitrobenzene, 4-Bromo-1-methoxy-2-nitrobenzene, 4-Bromo-2-nitrophenyl methyl ether;Benzene, 4-bromo-1-methoxy-2-nitro-
• CAS NO: 33696-00-3
• Molecular Formula: C₇H₆BrNO₃
• Molecular Weight: 232.03
• EINECS: 251-642-5
• Product Categories: blocks;Bromides;NitroCompounds;Aromatic Halides (substituted);Halides;Phenyls & Phenyl-Het;Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds;Nitro Compounds;Phenyls & Phenyl-Het
• Mol File: 33696-00-3.mol
• Article Data: 18

Chemical Properties

• Melting Point: 87 °C
• Boiling Point: 303.3 °C at 760 mmHg
• Flash Point: 137.2 °C
• Appearance: /Solid
• Density: 1.640
• Vapor Pressure: 0.00168mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-BROMO-2-NITROANISOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-NITROANISOLE(33696-00-3)
• EPA Substance Registry System: 4-BROMO-2-NITROANISOLE(33696-00-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 33696-00-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-nitroanisole is a chemical compound whose molecular formula is C7H6BrNO3. It has a molar mass of 232.03 g/mol. 4-Bromo-2-nitroanisole is used in the industry as an intermediate for the synthesis of various pharmaceutical and chemical products. It appears as a brown solid with a distinctly aromatic smell. 4-Bromo-2-nitroanisole is known to be stable under normal temperatures and pressures, but it can react with oxidizing agents. 4-Bromo-2-nitroanisole should be handled with care as, like most chemicals, it can cause harm to the skin and eyes on contact, and if ingested or inhaled, it can be harmful or fatal.

InChI:InChI=1/C7H6BrNO3/c1-12-7-3-2-5(8)4-6(7)9(10)11/h2-4H,1H3

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 509-14-8 tetranitromethane 
• 610-38-8 4-bromo-1,2-dinitrobenzene 
• 124-41-4 sodium methylate 
• 7693-52-9 4-bromo-2-nitrophenol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 364-76-1 4-Fluoro-3-nitroaniline 
• 577-72-0 4-methoxy-3-nitroaniline 
• 106-95-6 allyl bromide 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 91-23-6 2-Nitroanisole 
• 7726-95-6 bromine 

Downstream Products

• 78805-55-7 4-(4-methylphenoxy)-2-nitroanisole 
• 7693-52-9 4-bromo-2-nitrophenol 
• 89-64-5 p-chloro-o-nitrophenol 
• 87815-76-7 4-bromo-N-cyclohexyl-2-nitroaniline 
• 1034617-86-1 1-(4-methoxy-3-nitrophenyl)-4-methylpiperazine 
• 1423711-80-1 C₁₉H₂₃NO₄ 
• 1423711-82-3 C₁₉H₂₃NO₄ 
• 4394-02-9 2-(4-methoxy-3-nitrophenyl)pyridine 
• 15854-73-6 3-nitro-4-methoxybiphenyl 
• 1070195-62-8 1-(3'-amino-4'-methoxyphenyl)-1-(3'',4'',5''-trimethoxyphenyl)ethylene 

Relevant articles and documents

Weak Links to Differentiate Weak Bonds: Size-Selective Response of π-Conjugated Macrocycle Gels to Ammonium Ions

Molecular-level host-guest interactions can drive gel-to-sol phase transitions of the bulk material. Using supramolecular gels constructed from π-conjugated aza-crown macrocycles, we have investigated the effects of guest chemical structures on the kinetics of gel disassembly. While ammonium ions bind only weakly to the individual macrocycles in solution, gel-to-sol transitions of self-assembled macrocycles occur readily under ambient conditions. This net signal amplification process was monitored conveniently by time-dependent spectroscopic studies to reveal a straightforward correlation between the response rate and shape/size of the guest species. Well-designed weak links thus respond to subtle differences in weak bonds and translate them into visually discernible macroscopic signaling events.

Sulfonamide compound and medical applications thereof

The invention discloses a compound containing a sulfonamide structure, a preparation method thereof, and medical applications of the compound, and more specifically discloses the compound with a structure represented by formula I, and a pharmaceutically acceptable salt or a prodrug or a solvate thereof. The compound is used for tumor treatment through inhibiting ATP-citrate lyase.

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.